The effects of dose, nutrition, and age on hexarelin-induced anterior pituitary hormone secretion in adult patients on maintenance hemodialysis

Journal of Clinical Endocrinology and Metabolism

Volumn 84, Issue 4, 1999, Pages 1220-1225

  Jenkins, Richard C ^a   El Nahas, A Meguid ^b   Wilkie, Martin E ^b   Brown, Colin B ^b   Jones, Jenny ^c   Ghigo, Ezio ^d   Ross, Richard J M ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NORTHERN GENERAL HOSPITAL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; GROWTH HORMONE; HEXARELIN; HYDROCORTISONE; PROLACTIN;

ADENOHYPOPHYSIS; ADULT; AGE; AGED; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; HEMODIALYSIS; HORMONE RELEASE; HUMAN; NUTRITIONAL STATUS; PRIORITY JOURNAL; PROTEIN CALORIE MALNUTRITION;

EID: 0033323821     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.84.4.1220     Document Type: Article

References (33)

1. Death risk of haemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities
2. Neuroendocrine alterations in the somatotropic axis in chronic renal failure
3. Alteration of pituitary thyroid function in patients with chronic renal failure treated by haemodialysis or continuous ambulatory peritoneal dialysis
4. The effects of corticotropin and growth hormone releasing hormones on their respective secretory axes in chronic hemodialysis patients before and after correction of anemia with recombinant human erythropoietin
5. Insulin-like growth factors (IGFs) and IGF binding proteins in chronic renal failure; evidence for reduced secretion of IGFs
6. IGF-I, A marker of under-nutrition in hemodialysis patients
7. The rationale for the use of growth hormone or insulin-like growth factor-I in adult patients with renal failure
8. A receptor in pituitary and hypothalamus that functions in growth hormone release
9. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal and oral administration in man
10. Growth hormone releasing activity of hexarelin in humans:A dose-response study
11. The effect of an opiate antagonist on the hormonal changes induced by hexarelin
12. Hexarelin, a synthetic growth hormone releasing peptide, stimulates prolactin secretion in acromegalic but not in hyperprolactinemic patients
13. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subiects
14. Modulation of growth hormone-releasing activity of hexarelin in man
15. Intranasal administration of the GHRP hexarelin accelerates growth in short children
16. Pituitary, responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness
17. Neuroendocrinology of prolonged critical illness: Effects of exogenous thyrotrophin-releasing hormone and its combination with growth hormone secretagogues
18. The somatotropic axis in critical illness: Effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion
19. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism
20. Hexarelin induced growth hormone release is influenced by exogenous growth hormone
21. Serum growth hormone and glucose intolerance in renal failure
22. Abnormalities in the regulation of growth hormone in chronic renal failure
23. Subjective global assessment as it pertains to the nutritional status of dialysis patients
24. Skinfold measurements
25. The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin
26. Adrenocorticotropin-cortisol axis abnormalities in haemodialysis patients
27. Adrenal responsiveness in chronic hemodialysis
28. Free insulin-like growth factor-I in healthy subjects: Relationship with IGF-binding proteins and insulin sensitivity
29. IGF-I/IGFBP-1 as an index for discrimination between responder and non-responder to recombinant human growth hormone in malnourished uremic patients on hemodialysis
30. Recombinant human growth hormone therapy in malnourished dialysis patients: A randomized controlled study
31. Accelerated growth after recombinant human growth hormone treatment of children with chronic renal failure
32. Placebo-controlled, double-blind, cross-over trial of growth hormone treatment in prepubertal children with chronic renal failure
33. Growth hormone status during long-term hexarelin therapy